• June 3-6, 2024
  • San Diego Convention Center, California



Future Medicine

Monday, June 03, 2024
Metabolic Diseases
Future Medicine (hereinafter referred to as "we") is a bio-venture, focusing on nucleoside-based drug development company. we directly synthesize new drug candidates based on the nucleoside compound library of “FOCUS” (Futuremedicine Origin Compound Library Universal System), a self-built synthetic material derivation platform for drug development, and research and develop new drugs that can treat target diseases by regulating various in vivo targets involving nucleoside. In particular, we are promoting research and commercialization of new drugs for intractable diseases for which there are no treatments in the global market through new drug candidates such as metabolic diseases, anticancer drugs, and antiviral drugs, which are the main pipeline. We are expanding our pipelines with metabolic disease such as NASH and obesity, also innovative compounds for oncology area. From our FOCUS, we directly synthesizes and derive various new drug candidates for next pipelines.
Future Medicine
Company Website: http://www.futuremedicine.co.kr
Lead Product in Development: FM101 Lead asset, FM101, is a nucleoside drug that is an antagonist of A3 adenosine receptor (A3AR), and we are developing it as a treatment for non-alcoholic steatohepatitis (NASH), a metabolic disease, as its anti-inflammatory and anti-fibrotic effects have been confirmed through initial studies. currently phase 2a clinical trial is ongoing. FM801 FM801 burns fat by converting energy-storing white fat to brown fat through modulation of adenosine receptors in the body, which we believe may have therapeutic benefits for obesity and associated metabolic diseases. Our nonclinical results demonstrated equivalent weight loss by fat burning without muscle loss compared to existing GLP-1 analogs, and maintenance of weight loss without regain when the drug is discontinued. We also expect no gastrointestinal or psychiatric side effects, which we published in the International Journal of Obesity (2022) 462128-2136.
Number Of Unlicensed Products (For Which You Are Seeking Partners): 3





Company HQ City


Company HQ State


Company HQ Country

Korea, Republic of

CEO/Top Company Official

Wanseok Jeong, MBA

Development Phase of Primary Product

Phase II
Back to Session List


Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.